Sandoval et al. discovered a methylation signature based on 10 sites (HOXA9, C1orf114, TRH, HIST1H4F, SP9, PCDHGB6, OTX2, NPBWR1, TRIM58, and ALX1) that effectively distinguished stage I NSCLC patients with high recurrence risk and low risk 57.Conventionally, molecular or epigenetic biomarkers are often identified by comparing the genomic or epigenomic landscapes of two groups with diverse outcomes. Here, ALX1 is linked to non-small cell lung carcinoma.